393 related articles for article (PubMed ID: 17239199)
1. Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis.
Zafranskaya M; Oschmann P; Engel R; Weishaupt A; van Noort JM; Jomaa H; Eberl M
Immunology; 2007 May; 121(1):29-39. PubMed ID: 17239199
[TBL] [Abstract][Full Text] [Related]
2. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415
[TBL] [Abstract][Full Text] [Related]
3. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
[TBL] [Abstract][Full Text] [Related]
4. Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis.
Krakauer M; Sorensen PS; Khademi M; Olsson T; Sellebjerg F
Scand J Immunol; 2006 Aug; 64(2):155-63. PubMed ID: 16867161
[TBL] [Abstract][Full Text] [Related]
5. Expansion of CD4+CD28- T cells producing high levels of interferon-{gamma} in peripheral blood of patients with multiple sclerosis.
Miyazaki Y; Iwabuchi K; Kikuchi S; Fukazawa T; Niino M; Hirotani M; Sasaki H; Onoé K
Mult Scler; 2008 Sep; 14(8):1044-55. PubMed ID: 18573819
[TBL] [Abstract][Full Text] [Related]
6. Peripheral blood T lymphocyte subsets in children with congenital asplenia.
Motkowski R; Michalkiewicz J; Mikoluc B; Smolka-Afifi D; Pietrucha B; Kubiszewska I; Piotrowska-Jastrzebska J; Bernatowska E
Hum Immunol; 2012 Nov; 73(11):1091-7. PubMed ID: 22902394
[TBL] [Abstract][Full Text] [Related]
7. T-cell responses to neurofilament light protein are part of the normal immune repertoire.
Huizinga R; Hintzen RQ; Assink K; van Meurs M; Amor S
Int Immunol; 2009 Apr; 21(4):433-41. PubMed ID: 19240089
[TBL] [Abstract][Full Text] [Related]
8. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
[TBL] [Abstract][Full Text] [Related]
9. IFNbeta-1a therapy for multiple sclerosis expands regulatory CD8+ T cells and decreases memory CD8+ subset: a longitudinal 1-year study.
Aristimuño C; de Andrés C; Bartolomé M; de las Heras V; Martínez-Ginés ML; Arroyo R; Fernández-Cruz E; Sánchez-Ramón S
Clin Immunol; 2010 Feb; 134(2):148-57. PubMed ID: 19900844
[TBL] [Abstract][Full Text] [Related]
10. Peripheral blood CD4+ T lymphocytes from multiple sclerosis patients are characterized by higher PSGL-1 expression and transmigration capacity across a human blood-brain barrier-derived endothelial cell line.
Bahbouhi B; Berthelot L; Pettré S; Michel L; Wiertlewski S; Weksler B; Romero IA; Miller F; Couraud PO; Brouard S; Laplaud DA; Soulillou JP
J Leukoc Biol; 2009 Nov; 86(5):1049-63. PubMed ID: 19696154
[TBL] [Abstract][Full Text] [Related]
11. Failure of glatiramer acetate to modify the peripheral T cell repertoire of relapsing-remitting multiple sclerosis patients.
Berthelot L; Miqueu P; Pettré S; Guillet M; Moynard J; Wiertlewski S; Lefrère F; Brouard S; Soulillou JP; Laplaud DA
Clin Immunol; 2010 Apr; 135(1):33-42. PubMed ID: 20116333
[TBL] [Abstract][Full Text] [Related]
12. Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-beta treatment in patients with multiple sclerosis.
Wiesemann E; Deb M; Trebst C; Hemmer B; Stangel M; Windhagen A
Mult Scler; 2008 Mar; 14(2):166-76. PubMed ID: 17942524
[TBL] [Abstract][Full Text] [Related]
13. CD8+ T-cell subsets defined by expression of CD45 isoforms differ in their capacity to produce IL-2, IFN-gamma and TNF-beta.
Adamthwaite D; Cooley MA
Immunology; 1994 Feb; 81(2):253-60. PubMed ID: 7908892
[TBL] [Abstract][Full Text] [Related]
14. Long-term favorable response to interferon beta-1b is linked to cytokine deviation toward the Th2 and Tc2 sides in Japanese patients with multiple sclerosis.
Mei FJ; Osoegawa M; Ochi H; Minohara M; Nan S; Murai H; Ishizu T; Taniwaki T; Kira J
J Neurol Sci; 2006 Jul; 246(1-2):71-7. PubMed ID: 16581087
[TBL] [Abstract][Full Text] [Related]
15. Lymphocyte calcium influx kinetics in multiple sclerosis treated without or with interferon β.
Toldi G; Folyovich A; Simon Z; Zsiga K; Kaposi A; Mészáros G; Tulassay T; Vásárhelyi B
J Neuroimmunol; 2011 Aug; 237(1-2):80-6. PubMed ID: 21764463
[TBL] [Abstract][Full Text] [Related]
16. Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions.
Kerlero de Rosbo N; Hoffman M; Mendel I; Yust I; Kaye J; Bakimer R; Flechter S; Abramsky O; Milo R; Karni A; Ben-Nun A
Eur J Immunol; 1997 Nov; 27(11):3059-69. PubMed ID: 9394837
[TBL] [Abstract][Full Text] [Related]
17. Thymic output and peripheral T lymphocyte subsets in relapsing--remitting multiple sclerosis patients treated or not by IFN-beta.
Puissant-Lubrano B; Viala F; Winterton P; Abbal M; Clanet M; Blancher A
J Neuroimmunol; 2008 Jan; 193(1-2):188-94. PubMed ID: 18068811
[TBL] [Abstract][Full Text] [Related]
18. Increased CD8+ central memory T cells in patients with multiple sclerosis.
Liu GZ; Fang LB; Hjelmström P; Gao XG
Mult Scler; 2007 Mar; 13(2):149-55. PubMed ID: 17439879
[TBL] [Abstract][Full Text] [Related]
19. Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein.
Harp CT; Ireland S; Davis LS; Remington G; Cassidy B; Cravens PD; Stuve O; Lovett-Racke AE; Eagar TN; Greenberg BM; Racke MK; Cowell LG; Karandikar NJ; Frohman EM; Monson NL
Eur J Immunol; 2010 Oct; 40(10):2942-56. PubMed ID: 20812237
[TBL] [Abstract][Full Text] [Related]
20. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis.
Haas J; Hug A; Viehöver A; Fritzsching B; Falk CS; Filser A; Vetter T; Milkova L; Korporal M; Fritz B; Storch-Hagenlocher B; Krammer PH; Suri-Payer E; Wildemann B
Eur J Immunol; 2005 Nov; 35(11):3343-52. PubMed ID: 16206232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
